Company Drug

Biogen’s Salanersen Shows 75% NfL Reduction in SMA Phase Ib – Once-Yearly ASO Advances to Phase III

By Fineline Cube #Biogen #Clinical trial results #NASDAQ: BIIB #RNAi / ASO
Biogen's Salanersen Shows 75% NfL Reduction in SMA Phase Ib – Once-Yearly ASO Advances to Phase III

Biogen Inc. (NASDAQ: BIIB) presented supplemental Phase Ib data for salanersen, its investigational antisense oligonucleotide (ASO) for spinal muscular atrophy (SMA), at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. The once-yearly administered therapy demonstrated substantial neurofilament light chain (NfL) reductions up to 75% at 6 months in participants with elevated baseline levels, with all 24 treated patients showing improvements in endpoint measures and 50% achieving new WHO motor milestones. The 80 mg dose is now being evaluated in Phase III, positioning salanersen as a potential best-in-class SMA treatment with dramatically reduced dosing burden versus existing therapies.

Clinical Data Summary

EndpointSalanersen (40 mg / 80 mg)Outcome
NfL ReductionUp to 75% at 6 monthsSubstantial neuronal degeneration marker improvement
NfL MaintenanceSustained throughout follow-upDurable treatment effect
Motor Milestones12/24 (50%) achieved ≥1 new WHO motor milestoneFunctional improvement
Motor Preservation24/24 (100%) maintained baseline motor abilitiesNo disease progression
Overall Improvement24/24 (100%) showed improvement in ≥1 endpointUniversal treatment benefit
SafetyGenerally well-tolerated; mostly mild-moderate AEsFavorable tolerability profile

Study Population:

  • N=24 participants aged 0.5-12 years
  • Prior Treatment: All received ≥2 doses of salanersen (40 mg or 80 mg)
  • Biomarker Focus: NfL (neurofilament light chain) – marker of axonal injury/neurodegeneration

Drug Profile & Differentiation

AttributeSalanersen Specification
Drug ClassAntisense oligonucleotide (ASO)
TargetSMN2 splicing modifier (increases functional SMN protein)
MechanismPromotes exon 7 inclusion in SMN2 mRNA → increased survival motor neuron (SMN) protein production
Dosing FrequencyOnce-yearly (vs. quarterly for Spinraza, daily for Evrysdi)
RouteIntrathecal injection
Development StagePhase Ib (completed); Phase III (ongoing with 80 mg dose)

Competitive Positioning vs. Standard of Care:

ProductDeveloperMechanismDosingSalanersen Advantage
Spinraza (nusinersen)BiogenSMN2 ASOEvery 4 months (intrathecal)Once-yearly frequency
Evrysdi (risdiplam)RocheSMN2 splicing modifierDaily oralReduced treatment burden; intrathecal delivery to CNS
ZolgensmaNovartisSMN1 gene therapyOne-time IVSalanersen for older patients; retreatment possible
BiogenSalanersenNext-gen SMN2 ASOOnce-yearlySuperior convenience; 75% NfL reduction; Phase III advancement

Strategic Context & Market Impact

FactorImplication
SMA Market EvolutionTransition from acute treatment to long-term management; dosing convenience increasingly valued
Biogen Franchise DefenseSalanersen protects Biogen’s SMA leadership against Spinraza LOE (loss of exclusivity 2028+)
NfL as Biomarker75% reduction validates target engagement; potential surrogate endpoint for accelerated approval
Pediatric Expansion0.5-12 year data supports broad age indication; pre-symptomatic treatment potential
Phase III Timing80 mg dose selection based on Phase Ib efficacy/safety; registrational data anticipated 2027-2028

Development Outlook

PhaseTimelineObjectives
Phase IbCompleteDose-ranging (40 mg, 80 mg); NfL biomarker validation; safety profile
Phase IIIOngoing (2025-2028)80 mg dose efficacy vs. standard of care; motor function endpoints; long-term safety
Regulatory Filing2028-2029U.S., EU, Japan NDAs; breakthrough therapy designation potential
Commercial Launch2029-2030Spinraza replacement strategy; premium pricing for convenience advantage

Forward‑Looking Statements
This brief contains forward‑looking statements regarding Phase III outcomes, NfL biomarker validation, and competitive positioning for salanersen in spinal muscular atrophy. Actual results may differ due to long-term safety monitoring, competitive dynamics with gene therapy, and pricing negotiations for convenience premium.-Fineline Info & Tech

Related Post

Company Drug

Novartis’ Cosentyx Wins FDA Pediatric Approval – Only IL-17A Inhibitor for Hidradenitis Suppurativa in Adolescents 12+

Fineline Cube
Company Drug

Cutia Therapeutics’ CU-40105 Wins NMPA Approval – Topical Dutasteride Targets Androgenetic Alopecia with Reduced Systemic Exposure

Fineline Cube
Company Drug Medical Device

J&J’s Erda-iDRS Shows 89% Complete Response in NMIBC – Intravesical Erdafitinib System Advances to Phase II/III

Fineline Cube

You Missed

Company Drug

Novartis’ Cosentyx Wins FDA Pediatric Approval – Only IL-17A Inhibitor for Hidradenitis Suppurativa in Adolescents 12+

Company Drug

Cutia Therapeutics’ CU-40105 Wins NMPA Approval – Topical Dutasteride Targets Androgenetic Alopecia with Reduced Systemic Exposure

Company Drug Medical Device

J&J’s Erda-iDRS Shows 89% Complete Response in NMIBC – Intravesical Erdafitinib System Advances to Phase II/III

Company Drug

BeBetter Medicine’s Ifupinostat Wins NMPA Approval for PTCL Trial – First HDAC/PI3Kα Dual Inhibitor Enters First-Line Lymphoma Study